Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19

NCT04412772 is registered in ClinicalTrials.gov with Queen's Medical Center as lead sponsor.

NCT NCT04412772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04412772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19
Lead sponsor
Queen's Medical Center
Phase
Phase 3
Overall status
Terminated
Start date
June 12, 2020
Completion date
March 31, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19